German Cancer Research Center-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2024

  1. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131

2016

  1. Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure

    Oncotarget, Vol. 7, Núm. 31, pp. 49008-49026

  2. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

  3. Recombinant AAV Integration Is Not Associated with Hepatic Genotoxicity in Nonhuman Primates and Patients

    Molecular Therapy, Vol. 24, Núm. 6, pp. 1100-1105

  4. Transient expression of transgenic IL-12 in mouse liver triggers unremitting inflammation mimicking human autoimmune hepatitis

    Journal of Immunology, Vol. 197, Núm. 6, pp. 2145-2156

2013

  1. Safety and liver transduction efficacy of raav5-cohpbgd in nonhuman primates: A potential therapy for acute intermittent porphyria

    Human Gene Therapy, Vol. 24, Núm. 12, pp. 1007-1017

2009

  1. Efficient recovery of HLA class i expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: Implications for cancer immunotherapy

    Scandinavian Journal of Immunology, Vol. 70, Núm. 2, pp. 125-135